Table 1

Baseline characteristics of patients (N=105)

CharacteristicValue (N=105)
Age, years, median (range)51 (31–75)
 <65 years, n (%)97 (92.4)
 ≥65 years, n (%)8 (7.6)
ECOG performance status, n (%)
 038 (36.2)
 167 (63.8)
Histology, n (%)
 Adenomatous carcinoma11 (10.5)
 Squamous carcinoma92 (87.6)
 Adenosquamous carcinoma2 (1.9)
FIGO stage at initial diagnosis, n (%)*
 IB21 (20.0)
 IIA23 (21.9)
 IIB23 (21.9)
 IIIA2 (1.9)
 IIIB11 (10.5)
 IIIC11 (10.5)
 IV10 (9.5)
 Unknown4 (3.8)
Previous treatment, n (%)
 Surgery75 (71.4)
 Radiotherapy100 (95.2)
 Chemotherapy105 (100.0)
Previous anti-neoplastic agents, n (%)
 Cisplatin81 (77.1)
 Carboplatin43 (41.0)
 Paclitaxel49 (46.7)
 Bevacizumab32 (30.5)
Lines of previous chemotherapy, n (%)
 164 (61.0)
 232 (30.5)
 ≥39 (8.6)
Expression of PD-L1 (CPS), n (%)
 1 to <2066 (62.9)
 ≥2039 (37.1)
  • Values are n (%) unless otherwise stated.

  • *International Federation of Gynecology and Obstetrics (FIGO) 2018. Combined positive score (CPS) (WD160; WuXi Diagnostics).

  • CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death ligand-1.